From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

Hugh, Jeremy; Voorhees, Abby S. Van; Nijhawan, Rajiv I.; Bagel, Jerry; Lebwohl, Mark; Blauvelt, Andrew; Hsu, Sylvia; Weinberg, Jeffrey M

doi:10.1016/j.jaad.2013.09.020

Cited by 134 publications

(118 citation statements)

References 132 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…However, the data on the CV safety of this strategy in these patients are conflicting, in part because of the limited number of events and short follow-up times in trials. 76 Yet, in preclinical studies, IL-12 blockade by vaccination resulted in significant atheroprotection in Ldlr -/-mice. 77 Elevated levels of IFNα have been reported in the sera of a subgroup of SLE patients, and hundreds of IFN-stimulated mRNA species are found in the blood of these patients.…”

Section: Induction Of Protective Treg Responsesmentioning

confidence: 99%

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –

Ketelhuth

Hansson

2015

Circ J

View full text Add to dashboard Cite

Section: Induction Of Protective Treg Responsesmentioning

confidence: 99%

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –

Ketelhuth

Hansson

2015

Circ J

View full text Add to dashboard Cite

“…Therefore, TNF inhibitors may also be effective in decreasing cardiac and cerebrovascular events in Pso or PsA. Several studies demonstrated decreased risk of cardiovascular events with TNF inhibitors treatment in Pso or PsA [5,6]. However, combining six clinical studies, Roubille et al did not found that targeting systemic inflammation with TNF inhibitors may have decrease cardiovascular events in Pso or PsA [7].…”

Section: Introductionmentioning

confidence: 99%

The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis

Yang

Lin

et al. 2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

TNF inhibitors have been used in psoriasis (Pso) and psoriatic arthritis (PsA), which were associated with increased risk of cardiac and cerebrovascular events. However, whether TNF inhibitors reduce cardiovascular event is still unclear. Therefore, we aimed to evaluate the effect of TNF inhibitors on adverse cardiovascular events (CVEs) in Pso with or without PsA. We undertook a meta-analysis of clinical trials identified in systematic searches of MEDLINE, EMBASE, Wanfang database, Cochrane Database, and Google scholar through December 31, 2015. Five studies (49,795 patients) were included. Overall, compared with topical/photo treatment, TNF inhibitors were associated with a significant lower risk of CVE (RR, 0.58; 95 % CI, 0.43 to 0.77; P < 0.001; I (2) = 66.2 %). Additionally, compared with methotrexate (MTX) treatment, risk of CVE was also markedly decreased in the TNF inhibitor group (RR, 0.67; 95 % CI, 0.52 to 0.88; P = 0.003; I (2) = 9.3 %). Meanwhile, TNF inhibitors were linked to reduced incidence of myocardial infarction compared with topical/photo or MTX treatment (RR, 0.73; 95 % CI, 0.59 to 0.90; P = 0.003; I (2) = 56.2 % and RR, 0.65; 95 % CI, 0.48 to 0.89; P = 0.007; I (2) = 0.0 %, respectively). Furthermore, there was a trend of decreased rate of mortality in the TNF inhibitor group compared with other therapy (RR, 0.90; 95 % CI, 0.54 to 1.50; P = 0.68; I (2) = 70.9 %). TNF inhibitors appear to have net clinical benefits with regard to adverse cardiovascular events in Pso and/or PsA. Rigorous randomized controlled trials will need to evaluate whether TNF inhibitors truly result in reduction of cardiovascular diseases.

show abstract

“…Activated T cells, inflammatory cells, and keratinocytes in psoriasis lesions (7) are capable of inducing VEGF secretion. The association between the incidence of psoriasis and the serum concentrations of VEGF has previously been confirmed (8). VEGF is recognized as an indicator of disease …”

Section: Discussionmentioning

confidence: 83%

Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report

Liu

Zhou

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Pyogenic granuloma (PG) is an acquired benign vascular tumor of unknown etiology. In the present case report, PG was detected in a 49-year-old Chinese male patient with chronic plaque psoriasis. The psoriasis lesions on the finger where the granuloma had developed had been scratched excessively, as declared by the patient. No retinoid therapeutic agents were used during treatment. The patient responded poorly to cryotherapy and surgical curettage. However, following one session of 5-aminolevulinic acid photodynamic therapy (ALA-PDT), signs of improvement were demonstrated 1 week after the treatment, and 1 month following treatment, there were no signs of reoccurrence. Although a report demonstrating treatment success in one patient may be inadequate to estimate the true efficiency of ALA-PDT, dermatologists may consider ALA-PDT as an alternative therapy for stubborn PG.

show abstract

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

Cited by 134 publications

References 132 publications

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –

The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis

Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report

Contact Info

Product

Resources

About

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

Cited by 134 publications

References 132 publications

Modulation of Autoimmunity and Atherosclerosis – Common Targets and Promising Translational Approaches Against Disease –

Modulation of Autoimmunity and Atherosclerosis – Common Targets and Promising Translational Approaches Against Disease –

The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis

Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report

Contact Info

Product

Resources

About

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –

Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –